14-17 June, 2017
Boston, Massachusetts
At the 2017 Annual Meeting of the International Society for Stem Cell Research (ISSCR), Fate Therapeutics hosted a Focus Session entitled “Off-the-Shelf Natural Killer Cell Cancer Immunotherapy”. The Focus Session featured renowned guest speakers and provided an in-depth overview of the Company’s off-the-shelf natural killer (NK) cell product candidate pipeline emerging from its industry-leading induced pluripotent stem cell (iPSC) platform. Fate Therapeutics and its collaborators are developing first-of-kind activated and tumor-targeted NK- and T-cell immunotherapies derived from master engineered pluripotent cell lines for the treatment of cancer.
